Virtual Tumor Board

This Urology Times® Virtual Tumor Board examines how PSMA PET is being integrated across the prostate cancer continuum, from initial staging through recurrent and metastatic disease. Faculty discuss advances beyond conventional imaging, differences among available PSMA PET radiotracers, biodistribution and interpretation pitfalls, and practical considerations such as access, reimbursement, supply, and geography. Three patient cases illustrate how PSMA PET findings can influence clinical decision-making: evaluating an indeterminate bone lesion, refining staging and treatment planning in newly diagnosed high-risk disease, and assessing disease distribution and PSMA expression in a patient with metastatic prostate cancer who is radioligand therapy–naive and being considered for PSMA-targeted radioligand therapy. Throughout the program, perspectives from urology, radiation oncology, and nuclear medicine highlight the importance of multidisciplinary interpretation and individualized application of PSMA PET in prostate cancer care.

This Urology Times® Virtual Tumor Board series explores contemporary management strategies across the advanced prostate cancer continuum through four patient-centered case discussions. Expert faculty examine the impact of comorbidities, cardiovascular risk factors, cognitive function, quality-of-life considerations, and patient preferences on treatment selection and long-term disease management. The panel also discusses emerging approaches to high-risk biochemical recurrence, the evolving role of advanced imaging and treatment intensification, and how recent clinical trial and real-world evidence are shaping practice. Throughout the series, faculty emphasize the importance of individualized care, shared decision-making, and treating the whole patient—not just the cancer.

Neal Shore, MD; Sam Chang, MD, MBA; Max Kates, MD; and Katie Murray, DO, MS, discuss how the recent FDA approval of UGN-102 (mitomycin gel) provides a paradigm-shifting ablative treatment option for patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC), offering an alternative to repetitive surgical resections and potentially reducing the treatment burden through its sustained-release formulation that achieved 80% complete response rates in the ENVISION trial.

Ashish Kamat, MD, MBBS; Sam Chang, MD, MBA; Bogdana Schmidt, MD, MPH; and Katie Murray, DO, MS, discuss how management of non–muscle-invasive bladder cancer (NMIBC) requires careful risk stratification, standardized BCG therapy protocols, consideration of alternative treatments for BCG-unresponsive disease, gender-specific approaches, and specialized care for younger patients to improve outcomes and quality of life.

Panelists review four 4 clinical cases, discussing guideline-directed approaches to new and emerging treatment approaches in patients with hormone-sensitive and castration-resistant prostate cancer, as well as share sharing perspectives on key clinical trial data that may impact our decisions.

A panel of expert oncologists review clinical cases and provide a comprehensive discussion on the recent clinical advances in PSMA PET imaging for prostate cancer.

A panel of urology experts discuss advances in prostate cancer imaging and how it informs providers and influences patient care decision-making while reviewing several patient profiles.